Effect of a 12-hour subcutaneous infusion of somatostatin-14 on blood glucose, insulin and glucagon levels in healthy subjects and insulin dependent diabetics.
We compared the influence of a 12-hour subcutaneous infusion of somatostatin-14 on glucose homeostasis in two normal subjects and two insulin-dependent diabetics (IDD). In all cases, somatostatin infusion led to a decrease of blood glucose during the first hours. The diabetogenic effect of somatostatin was confirmed in normal subjects. Postprandial blood glucose response was exaggerated in one insulin-dependent diabetic while in the other, glucose tolerance was improved. Unexpected high levels of immunoreactive somatostatin were measured in insulin-dependent diabetic patients. They might be due to a decreased somatostatin catabolism.
D001786:Blood Glucose / Q000378:metabolism*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood*; D005934:Glucagon / Q000097:blood; D006801:Humans; D007263:Infusions, Parenteral; D007328:Insulin / Q000097:blood; D011863:Radioimmunoassay; D013004:Somatostatin / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*
D001786:Blood Glucose; D007328:Insulin; D013004:Somatostatin; D005934:Glucagon